Cargando…
Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129
The coronavirus disease 2019 (COVID-19) pandemic has been as unprecedented as unexpected, affecting more than 105 million people worldwide as of 8 February 2020 and causing more than 2.3 million deaths according to the World Health Organization (WHO). Not only affecting the lungs but also provoking...
Autores principales: | Badimon, Lina, Robinson, Emma L, Jusic, Amela, Carpusca, Irina, deWindt, Leon J, Emanueli, Costanza, Ferdinandy, Péter, Gu, Wei, Gyöngyösi, Mariann, Hackl, Matthias, Karaduzovic-Hadziabdic, Kanita, Lustrek, Mitja, Martelli, Fabio, Nham, Eric, Potočnjak, Ines, Satagopam, Venkata, Schneider, Reinhard, Thum, Thomas, Devaux, Yvan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083253/ https://www.ncbi.nlm.nih.gov/pubmed/33839767 http://dx.doi.org/10.1093/cvr/cvab094 |
Ejemplares similares
-
Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129
por: Gomes, Clarissa Pedrosa da Costa, et al.
Publicado: (2019) -
A Year in the Life of the EU-CardioRNA COST Action: CA17129 Catalysing Transcriptomics Research in Cardiovascular Disease
por: Robinson, Emma Louise, et al.
Publicado: (2020) -
Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: a position paper from the EU-CardioRNA COST action CA17129
por: Vanhaverbeke, Maarten, et al.
Publicado: (2021) -
Consensus guidelines for the validation of qRT-PCR assays in clinical research by the CardioRNA consortium
por: de Gonzalo-Calvo, David, et al.
Publicado: (2022) -
Noncoding RNAs in Hypertension
por: Jusic, Amela, et al.
Publicado: (2019)